HCW Biologics Inc. Quarterly Debt-to-equity in % from Q3 2022 to Q3 2024

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: HCW Biologics Inc. quarterly Debt-to-equity history and growth rate from Q3 2022 to Q3 2024.
HCW Biologics Inc. Debt-to-equity for the quarter ending September 30, 2024 was 1.79K %, a 5015% increase year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date
Q3 2024	1.79K	+1.76K	+5015%	Sep 30, 2024
Q2 2024	205	+177	+624%	Jun 30, 2024
Q1 2024	79.6	+60.4	+316%	Mar 31, 2024
Q4 2023	49.3	+37.4	+313%	Dec 31, 2023
Q3 2023	35.1	+27.7	+377%	Sep 30, 2023
Q2 2023	28.3			Jun 30, 2023
Q1 2023	19.1			Mar 31, 2023
Q4 2022	12			Dec 31, 2022
Q3 2022	7.35			Sep 30, 2022

* An asterisk sign (*) next to the value indicates that the value is likely invalid.